Tell the difference between cvid and Bruton disease

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I have enough data from the textbooks. Let me now compile the comprehensive comparison.

CVID vs. Bruton's Disease (X-Linked Agammaglobulinemia): A Detailed Comparison

Both are primary antibody (humoral) immunodeficiencies presenting with hypogammaglobulinemia and recurrent bacterial infections, but they differ fundamentally in genetics, pathophysiology, age of onset, B cell numbers, and clinical features.

1. Basic Overview

Feature	Bruton's Disease (XLA)	CVID
Full name	X-Linked Agammaglobulinemia	Common Variable Immunodeficiency
First described	1952 by Ogden Bruton	Variable entity, recognized ~1950s–1970s
Inheritance	X-linked recessive	Genetically heterogeneous (polygenic/multifactorial in most)
Sex affected	Males only	Both sexes equally
Prevalence	~1 in 190,000 male births	~1 in 20,000–50,000

2. Genetic Basis

Bruton's Disease:

Single-gene defect: mutations in BTK (Bruton tyrosine kinase gene), located on the X chromosome (Xq21.33–q22)
BTK is essential for B-cell receptor (BCR) signaling - specifically for phosphorylation of phospholipase Cγ2 and survival/differentiation signals from the pre-BCR and BCR
Because it is X-linked, only males are affected; females are carriers
(~85% of hereditary agammaglobulinemia is XLA; the remaining 15% are autosomal recessive forms due to mutations in IGHM, IGLL1, CD79, BLNK, PIK3R1, or TCF3)

CVID:

Genetically heterogeneous - mutations in over 50 genes have been implicated, but in >90% of cases the genetic basis remains unknown
Known mutations include: TACI (~5-10%), ICOS, BAFF-R (TNFRSF1C), CTLA4, LRBA, XIAP, PIK3CD, PIK3R1, NFkB1, CD19, CD20, CD21, CD81
Familial clustering occurs in ~10% of cases; can be dominant or recessive
Genetic overlap exists with selective IgA deficiency (some families carry members with both disorders, suggesting a shared underlying defect)

3. Pathophysiology (Block in B-Cell Development)

Feature	Bruton's Disease (XLA)	CVID
Block in B-cell maturation	Early - at pro-B cell → pre-B cell transition in bone marrow	Late - mature B cells present but cannot differentiate into plasma cells
B cells in blood/tissues	Absent or near-absent (<2% of lymphocytes)	Normal or near-normal numbers
Plasma cells	Absent	Absent (despite normal B cell numbers)
T cells	Normal	Often abnormal (~40% of patients have T cell abnormalities: anergy, lymphopenia, poor proliferative responses)
Germinal centers	Absent/hypoplastic	Hyperplastic (B cells proliferate in response to antigen but cannot differentiate into plasma cells)
Tonsils/lymph nodes	Small or absent	Often enlarged due to follicular hyperplasia

The core difference: In XLA, BTK loss stops B-cell development before maturity, so there are almost no B cells at all. In CVID, B cells develop normally but are blocked at the terminal differentiation step into plasma cells, so B cells pile up in germinal centers but antibody production fails.

4. Immunoglobulin Profile

Ig Class	Bruton's Disease	CVID
IgG	Absent (agammaglobulinemia)	Low (usually <450 mg/dL)
IgA	Absent	Low or absent
IgM	Absent	Low or absent (sometimes only IgG is low)
IgE	Absent	Low
Maternal IgG	Normal for first 6 months (protective)	Normal in childhood-onset cases

XLA = true agammaglobulinemia (all Ig classes absent). CVID = hypogammaglobulinemia (low but not necessarily zero).

5. Age of Onset

	Bruton's Disease	CVID
Typical onset	6–12 months of age (when maternal IgG wanes)	2nd–3rd decade of life (adolescence or adulthood, mean onset in 3rd decade)
Diagnosis delay	Usually diagnosed in infancy/early childhood	Can be delayed up to 10 years after symptom onset
Earliest symptoms	Recurrent infections after 6 months	Recurrent respiratory infections in adulthood

6. Clinical Manifestations

Shared features (both conditions):

Recurrent sinopulmonary infections (sinusitis, otitis media, bronchitis, pneumonia) - most commonly caused by encapsulated bacteria: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
Susceptibility to Giardia lamblia (persistent diarrhea)
Enterovirus infections (echovirus causing meningoencephalitis)
Bronchiectasis as a long-term complication
High frequency (~20%) of autoimmune diseases (RA, autoimmune cytopenias, etc.)
Treatment: IVIG or SCIG replacement

Features more prominent in XLA:

Concomitant neutropenia (25% of patients, because BTK is also expressed on myeloid cells)
Susceptibility to Mycoplasma pneumoniae and Ureaplasma urealyticum
Disseminated echovirus encephalitis (historically a major cause of mortality)
GI infections (10% prevalence of chronic gastroenteritis) - less common than in CVID
Absent tonsils and lymph nodes on physical exam

Features more prominent in CVID (due to T-cell co-dysfunction):

Lymphoproliferation and splenomegaly (expanded B cells in germinal centers)
Granulomatous disease (lungs, liver, spleen, lymph nodes - "granulomatous-lymphocytic interstitial lung disease")
Autoimmune cytopenias (immune thrombocytopenia, autoimmune hemolytic anemia)
Inflammatory bowel disease / colitis
Recurrent herpesvirus infections (~20% of patients)
Increased risk of lymphoma and gastric carcinoma (malignancies are a major cause of death in CVID)
Nodular regenerative hyperplasia of the liver

7. Laboratory Diagnosis

Test	Bruton's Disease	CVID
Serum Ig levels	All markedly reduced/absent	IgG low (<450 mg/dL); IgA and/or IgM low
B cell count (flow cytometry)	Markedly reduced (<2% of lymphocytes)	Normal or mildly reduced
T cell count	Normal	Often reduced or functionally abnormal
BTK protein (flow cytometry)	Absent - diagnostic	Normal
Vaccine responses	Absent	Poor/absent
Switched memory B cells (CD27+)	N/A (no B cells)	Often reduced - predicts risk of granuloma/splenomegaly/lymphoproliferation
Genetic testing	BTK mutation (confirms and allows carrier detection)	Whole-exome sequencing (positive in ~25% of severe/early-onset cases)

8. Treatment

Both conditions are treated primarily with immunoglobulin replacement therapy (IVIG or SCIG), at doses of 400-600 mg/kg/month:

SCIG has fewer infusion-related reactions than IVIG
High-dose therapy is superior to conventional dosing for infection prevention
Serologic assays for diagnosing infections are unreliable in both - must use PCR or cultures

Note: Serological antibody tests for infections (e.g., EBV, CMV titers) give false results in these patients because they cannot mount antibody responses. Direct microbial detection (PCR, culture) must be used instead.

CVID-specific: Depending on genetic cause, some patients may respond to immunomodulatory therapies targeting T cell dysregulation (e.g., CTLA4-Ig for CTLA4 mutations, mTOR inhibitors for PIK3CD gain-of-function).

Summary Table

Feature	Bruton's Disease (XLA)	CVID
Gene	BTK (single gene, X-linked)	Multiple genes (>50), often unknown
Sex	Males only	Both sexes
Age of onset	Infancy (6–12 months)	Adulthood (2nd–3rd decade)
B cells	Absent	Normal or near-normal
Plasma cells	Absent	Absent
T cells	Normal	Often abnormal (40%)
Ig levels	Agammaglobulinemia (all absent)	Hypogammaglobulinemia (low, especially IgG)
Tonsils/nodes	Small/absent	Enlarged (hyperplastic)
Splenomegaly	Uncommon	Common
Lymphoma risk	Moderate	Higher (major cause of death)
Granulomas	Rare	Common (lungs, liver, spleen)
Autoimmunity	~20%	~20% (more prominent)
Pathophysiology	Block at pro-B → pre-B transition	Block at B cell → plasma cell transition
Treatment	IVIG/SCIG	IVIG/SCIG ± targeted therapies

Sources:

Robbins, Cotran & Kumar Pathologic Basis of Disease, pp. 233–234
Robbins & Kumar Basic Pathology, p. ~763–776
Murray & Nadel's Textbook of Respiratory Medicine, pp. 2902–2905
Sleisenger and Fordtran's GI and Liver Disease, p. 2080
Harrison's Principles of Internal Medicine 22E, pp. 2334–2339

This is a shared conversation. Sign in to Orris to start your own chat.